Javascript must be enabled to continue!
HPV Vaccination and Hearing Trouble: A Population-Based Analysis
View through CrossRef
Introduction
Hearing loss is a widespread public health concern associated with cognitive, social, and quality-of-life impairments. Although the human papillomavirus (HPV) vaccine is primarily administered to prevent HPV-related cancers, there is growing interest in its broader health associations, including potential effects on hearing. To date, little is known about whether HPV vaccination is associated with hearing-related outcomes at the population level.
Methods
We analyzed data from 11,737 participants in the 2021–2023 cycles of the National Health and Nutrition Examination Survey (NHANES). Hearing status was determined through self-report and dichotomized as good hearing versus hearing trouble. HPV vaccine status was based on self-reported receipt of at least one dose. Multivariable logistic regression was used to examine the association between HPV vaccination and hearing trouble, adjusting for age, gender, education, and marital status.
Results
Among participants, 80.2% reported good hearing and 19.8% reported some degree of hearing trouble. HPV vaccination rates were slightly lower among those with hearing trouble (33.5%) compared to those with good hearing (36.9%). However, HPV vaccine status was not significantly associated with hearing trouble in adjusted analysis (OR = 1.05, 95% CI: 0.80–1.37, p = 0.717). Older age was associated with higher odds of hearing trouble (OR = 1.03 per year, p < 0.001), while female gender was protective (OR = 0.73, p = 0.007). Marital status and education level were not significantly associated with hearing outcomes.
Discussion
In this nationally representative sample, we found no evidence that receipt of the HPV vaccine is associated with increased risk of hearing trouble. These findings align with prior research indicating a lack of strong population-level evidence for otologic side effects following HPV vaccination. Our results also reinforce the well-established associations between hearing trouble, older age, and male gender. Further research using longitudinal data and objective audiologic assessments is warranted to confirm these findings and explore potential long-term effects.
Physician's Journal of Medicine
Title: HPV Vaccination and Hearing Trouble: A Population-Based Analysis
Description:
Introduction
Hearing loss is a widespread public health concern associated with cognitive, social, and quality-of-life impairments.
Although the human papillomavirus (HPV) vaccine is primarily administered to prevent HPV-related cancers, there is growing interest in its broader health associations, including potential effects on hearing.
To date, little is known about whether HPV vaccination is associated with hearing-related outcomes at the population level.
Methods
We analyzed data from 11,737 participants in the 2021–2023 cycles of the National Health and Nutrition Examination Survey (NHANES).
Hearing status was determined through self-report and dichotomized as good hearing versus hearing trouble.
HPV vaccine status was based on self-reported receipt of at least one dose.
Multivariable logistic regression was used to examine the association between HPV vaccination and hearing trouble, adjusting for age, gender, education, and marital status.
Results
Among participants, 80.
2% reported good hearing and 19.
8% reported some degree of hearing trouble.
HPV vaccination rates were slightly lower among those with hearing trouble (33.
5%) compared to those with good hearing (36.
9%).
However, HPV vaccine status was not significantly associated with hearing trouble in adjusted analysis (OR = 1.
05, 95% CI: 0.
80–1.
37, p = 0.
717).
Older age was associated with higher odds of hearing trouble (OR = 1.
03 per year, p < 0.
001), while female gender was protective (OR = 0.
73, p = 0.
007).
Marital status and education level were not significantly associated with hearing outcomes.
Discussion
In this nationally representative sample, we found no evidence that receipt of the HPV vaccine is associated with increased risk of hearing trouble.
These findings align with prior research indicating a lack of strong population-level evidence for otologic side effects following HPV vaccination.
Our results also reinforce the well-established associations between hearing trouble, older age, and male gender.
Further research using longitudinal data and objective audiologic assessments is warranted to confirm these findings and explore potential long-term effects.
Related Results
Trajectories of and spatial variations in HPV vaccine discussions on Weibo, 2018-2023: a deep learning analysis
Trajectories of and spatial variations in HPV vaccine discussions on Weibo, 2018-2023: a deep learning analysis
SummaryResearch in contextEvidence before this studyWe first searched PubMed for articles published until November 2023 with the keywords “(“HPV”) AND (“Vaccine” or “Vaccination”) ...
Knowledge and perception of HPV vaccination among Lebanese mothers of children between nine and 17-year-old
Knowledge and perception of HPV vaccination among Lebanese mothers of children between nine and 17-year-old
AbstractbackgroundHuman papillomavirus (HPV) is one of the most prevalent sexually transmitted viruses in the world, and is associated with many medical conditions cervical cancer ...
(O-15) HPV infection and genotype distribution among male patients attending a sexual health clinic in Lima from 2024 to 2025
(O-15) HPV infection and genotype distribution among male patients attending a sexual health clinic in Lima from 2024 to 2025
Abstract
Introduction
Human papillomavirus (HPV) is a serious global public health problem due to its high prevalence and...
Evaluation of female university students’ knowledge, attitudes, and practices toward human papillomavirus infection and vaccination. Multicenter cross-sectional study
Evaluation of female university students’ knowledge, attitudes, and practices toward human papillomavirus infection and vaccination. Multicenter cross-sectional study
Abstract
Introduction
Having good knowledge and a favorable attitude toward human papillomavirus (HPV) and HPV vaccinations is the cornerstone for i...
High rate of non-vaccine-targeted high-risk HPV genotypes in Ethiopia: Its implication in future vaccine selection
High rate of non-vaccine-targeted high-risk HPV genotypes in Ethiopia: Its implication in future vaccine selection
Abstract
Since the distribution of high-risk HPV genotypes varies across countries, genotype-based vaccination is widely recommended to control the burden of cervical cance...
Cervical Cancer: What Vaccine in Senegal?
Cervical Cancer: What Vaccine in Senegal?
Introduction: Cervical cancer (CC) is first cancer in terms of frequency and mortality among women in Senegal. This is a public health problem hence the urgency of preventive measu...
Gender inequities regarding the HPV vaccination coverage in high-income countries: a systematic review and meta-analysis
Gender inequities regarding the HPV vaccination coverage in high-income countries: a systematic review and meta-analysis
Abstract
Objective
This systematic review aimed to systematically map the evidence and identify the knowledge gaps in the unive...
Prevalence of HPV in a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study
Prevalence of HPV in a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study
Introduction
Human papillomavirus (HPV) infection is a common sexually transmitted infection often associated with cancer development. This study aimed to estim...

